CCN5 activation by free or encapsulated EGCG is required to render triple‐negative breast cancer cell viability and tumor progression

Epigallocatechin‐3‐gallate (EGCG) has been considered an anticancer agent despite conflicting and discrepant bioavailability views. EGCG impairs the viability and self‐renewal capacity of triple‐negative breast cancer (TNBC) cells and makes them sensitive to estrogen via activating ER‐α. Surprisingl...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Pharmacol Res Perspect
Autores principales: Das, Amlan, Haque, Inamul, Ray, Priyanka, Ghosh, Arnab, Dutta, Debasmita, Quadir, Mohiuddin, De, Archana, Gunewardena, Sumedha, Chatterjee, Indranil, Banerjee, Snigdha, Weir, Scott, Banerjee, Sushanta K.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7981588/
https://ncbi.nlm.nih.gov/pubmed/33745223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.753
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares